Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...

A Springfield resident and local real estate entrepreneur, Evan Plotkin has just been awarded $15 million after a jury found ...